Trials / Withdrawn
WithdrawnNCT05867030
Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma
A Phase Ib/III Study to Evaluating the Efficacy and Safety of Parsaclisib in Combination With Rituximab and Lenalidomide Versus Rituximab in Combination With Lenalidomide in Subjects With Relapsed or Refractory Follicular Lymphoma
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase Ib/III, Multicenter, double-blinded study of Parsaclisib, a PI3Kδ Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lenalidomide | lenalidomide is administered orally |
| DRUG | rituximab | rituximab is administered intravenously |
| DRUG | parsaclisib | parsaclisib is administered orally |
Timeline
- Start date
- 2023-07-28
- Primary completion
- 2029-08-31
- Completion
- 2033-04-30
- First posted
- 2023-05-19
- Last updated
- 2023-10-17
Source: ClinicalTrials.gov record NCT05867030. Inclusion in this directory is not an endorsement.